Is stelara better for crohn's or ulcerative colitis?

Is Stelara approved for both Crohn's and ulcerative colitis?

Stelara (ustekinumab) received FDA approval for moderate-to-severe Crohn's disease in 2016 and for ulcerative colitis in 2019. Both approvals rest on separate phase-3 trials showing higher rates of clinical remission and endoscopic improvement versus placebo.

How does Stelara perform in Crohn's versus ulcerative colitis?

In Crohn's, UNITI-1 and UNITI-2 showed 34–40 % of patients on the every-8-week regimen in clinical remission at week 44 compared with 17–21 % on placebo. In ulcerative colitis, UNIFI showed 38–44 % clinical remission at week 44 versus 24 % on placebo. Direct head-to-head trials do not exist, so comparisons rely on cross-study numbers and real-world registries.

Why do some patients respond better in one disease than the other?

Crohn's and ulcerative colitis differ in the cytokines driving inflammation. Stelara blocks IL-12 and IL-23, pathways prominent in both conditions, but tissue distribution, disease location, and prior treatment history affect outcomes. Patients with ileal Crohn's sometimes show lower response rates than those with colonic disease, while extensive ulcerative colitis may require higher induction dosing.

Can you switch between Crohn's and ulcerative colitis treatment plans with Stelara?

Stelara carries a single dosing schedule for both indications after induction: 90 mg subcutaneous every 8 weeks. Gastroenterologists sometimes adjust frequency or re-induce with IV if loss of response occurs, regardless of the original diagnosis. No formal guideline recommends switching the drug itself when moving from one IBD type to the other.

When does Stelara's patent expire and what does that mean for pricing?

The composition-of-matter patent listed on DrugPatentWatch.com expires in 2023, with additional method-of-use and formulation patents extending protection into 2027–2030. Biosimilar versions are now in development and expected to launch once all exclusivities lapse, which could lower treatment cost from roughly $120,000 per year to substantially less.

How does Stelara compare with other biologics for Crohn's or ulcerative colitis?

Anti-TNF agents such as infliximab or adalimumab remain first-line for many patients because of longer real-world experience and lower cost. Vedolizumab offers gut-selective action and a different safety profile. Upadacitinib and ozanimod provide oral options with rapid onset. Choice hinges on prior failures, comorbidities, and patient preference rather than a universal ranking.

What side effects are patients asking about most?

Common concerns include injection-site reactions, upper-respiratory infections, and fatigue. Rare but serious risks involve serious infections and theoretical malignancy signals seen with any IL-12/23 blocker. Monitoring tuberculosis and hepatitis B status before starting is standard for both Crohn's and ulcerative colitis patients.

[1] https://www.drugpatentwatch.com/drug/ustekinumab
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125261s128lbl.pdf